Phreesia Adds Jon Kessler to Board of Directors

Phreesia ( (PHR) ) just unveiled an update.

On February 23, 2026, Phreesia announced the appointment of industry veteran Jon Kessler to its Board of Directors, effective April 6, 2026, bringing decades of experience leading technology-driven healthcare financial services companies such as WageWorks and HealthEquity. Kessler, regarded as an audit committee financial expert, is expected to support Phreesia’s strategy to strengthen its platform, launch new offerings and enhance shareholder value as it continues to expand its role in digital patient engagement.

The company also disclosed that long-serving directors Edward L. Cahill and Board Chair Michael Weintraub will retire at the 2026 Annual Meeting, after overseeing Phreesia from its founding through its 2019 IPO and subsequent growth to more than $460 million in trailing twelve-month revenue. Following their departure, the Board will shrink to seven members, six of them independent, reflecting a governance refresh that aims to balance continuity with new expertise as Phreesia consolidates its position as a leader in modernizing patient intake and activation across the U.S. healthcare system.

The most recent analyst rating on (PHR) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Phreesia stock, see the PHR Stock Forecast page.

Spark’s Take on PHR Stock

According to Spark, TipRanks’ AI Analyst, PHR is a Neutral.

Phreesia’s overall stock score is driven by strong financial performance and positive earnings call highlights, including revenue growth and strategic acquisitions. However, technical analysis indicates bearish momentum, and valuation metrics reflect profitability challenges, impacting the overall score.

To see Spark’s full report on PHR stock, click here.

More about Phreesia

Phreesia, Inc. is a healthcare technology company specializing in patient activation, providing digital tools that help patients take a more active role in their care. Founded in 2005, the company offers patient-driven solutions for intake, outreach and education to healthcare providers, life sciences firms and other organizations, enabling roughly 170 million U.S. patient visits in 2024 and focusing on efficiency, experience and outcomes.

Listed on the NYSE under the ticker PHR, Phreesia has scaled significantly since its 2019 IPO, growing revenue from about $100 million to more than $460 million for the twelve months ended October 31, 2025. Its platform now supports nearly one in seven patient visits across the U.S., underscoring its influence in modernizing the patient intake process and broader healthcare workflows.

Average Trading Volume: 1,644,119

Technical Sentiment Signal: Sell

Current Market Cap: $729.5M

For an in-depth examination of PHR stock, go to TipRanks’ Overview page.